Evidence map›Paper›PMID 40282442›Full record

ArticleCancers2025

Detection of

Srushti Borkar, Fenja Markus, Agnes Oetting, Stefanie Schmidt, Christine Vössing, David Horst, Markus Möbs, Elena I Braicu, Frank Griesinger, Katja Horling and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Exploration of targeted anti-tumor therapy · 2026
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Srushti BorkarDepartment of Internal Medicine-Oncology, Carl v. Ossietzky University of Oldenburg, Pius-Hospital, 26121 Oldenburg, Germany.
Fenja MarkusInstitut für Hämatopathologie Hamburg, 22547 Hamburg, Germany.
Agnes OettingInstitut für Hämatopathologie Hamburg, 22547 Hamburg, Germany.
Stefanie SchmidtInstitut für Hämatopathologie Hamburg, 22547 Hamburg, Germany.
Christine VössingInstitut für Hämatopathologie Hamburg, 22547 Hamburg, Germany.
David HorstInstitute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany.
Markus MöbsInstitute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany.
Elena I BraicuCharité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin and Berlin Institute of Health, Klinik für Gynäkologie mit Zentrum für Onkologische Chirurgie und Klinik für Gynäkologie, 13353 Berlin, Germany.
Frank GriesingerDepartment of Internal Medicine-Oncology, Carl v. Ossietzky University of Oldenburg, Pius-Hospital, 26121 Oldenburg, Germany.
Katja HorlingInstitut für Hämatopathologie Hamburg, 22547 Hamburg, Germany.
Katharina TiemannInstitut für Hämatopathologie Hamburg, 22547 Hamburg, Germany.
Lukas C HeukampPius-Hospital, Klinik für Hämatologie und Onkologie, Universitätsklinik Innere Medizin Onkologie, Universitätsmedizin Oldenburg, 26121 Oldenburg, Germany.
Eva-Maria WillingInstitut für Hämatopathologie Hamburg, 22547 Hamburg, Germany.ORCID 0000-0002-5202-9214
Claudia VollbrechtInstitute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany.ORCID 0000-0002-0861-001X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodsWe evaluated NGS results of a pan-cancer cohort of almost 6000 patients from two major German institutes of pathology, to show that the occurrence of

resultsWe show the results of routine diagnostic analysis of the first consecutive 354 patients with activating

conclusionsOur findings not only corroborate prior research concerning the rarity of these mutations in unselected patients but also emphasize the importance of robust and broad molecular assays rather than single gene assays in their detection and characterization in the diagnostic setting. Advantages of different approaches are discussed to address the current clinical need.

Indexed as

ctDNAendocrine therapyESR1 mutationHR+ metastatic breast cancerliquid biopsyNGS

Identifiers

PMID40282442
PMCPMC12025842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.